Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular Robotic Surgical System in Peripheral Vascular Interventions.

The company is now set to file its 510(k) submission with the FDA by the end of 2024 and plans to accelerate its go-to-market strategy upon clearance.

Likely Trend of MBOT Stock Following the News

Following the news, shares of MBOT rose 0.3% to $0.96 at yesterday’s closing.

Shares of MBOT have plunged 41.2% year to date against the industry’s 7.8% growth. The S&P 500 has risen 22.9% in the same time frame.

Microbot Medical’s successful completion of the ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System signals positive investor sentiment. The LIBERTY system's potential to revolutionize endovascular procedures by reducing costs, improving physician experience and enabling remote operations positions it as a groundbreaking advancement, driving positive price performance.

Image Source: Zacks Investment Research

Significance of MBOT's ACCESS-PVI Trial for LIBERTY System

The successful completion of the ACCESS-PVI trial marks a significant milestone for Microbot Medical, demonstrating the effectiveness of the LIBERTY system in clinical settings. This accomplishment not only strengthens the company’s position in the healthcare market but also supports the 510(k) submission to the FDA and sets the stage for future commercialization efforts. The encouraging results from the trial, along with positive feedback from physicians, signify strong prospects for Microbot Medical and its innovative robotic surgical technologies.

Management expressed satisfaction with the LIBERTY system’s performance in its clinical trial.  It plans to present results in early 2025. The company sees the trial's conclusion as a major achievement and is focused on finalizing the FDA submission and preparing for commercialization.

With plans to build a commercial infrastructure and hire experienced healthcare executives for sales, Microbot is preparing for a potential launch in the second quarter of 2025, following the anticipated FDA approval.

Market Prospects Favoring MBOT

Per a report in Grand View Research, the global peripheral vascular devices market size is estimated to be worth $10.4 billion in 2024. It is anticipated to reach $14.8 billion by 2030 at a CAGR of 5.9%.

The robust growth is likely to be driven by the increasing incidence of cardiac diseases, the rising global geriatric population base triggering incidence rates of target diseases, novel product launches and an increase in collaboration and mergers by key players.